Apitope is a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases. We use our novel, proprietary discovery platform to select and develop highly specific peptide-based therapies, known as “apitopes®”, which restore the natural balance (immune tolerance) of the immune system. This mechanism of action avoids global immune suppression and has the broad potential to treat a wide variety of autoimmune diseases. Apitope’s lead product candidate ATX-MS-1467 is in clinical development for treating multiple sclerosis (“MS”). ATX-MS-1467 is the first potential therapeutic for MS that combines high efficacy with an excellent, and thereby differentiating, safety profile. Apitope’s other lead product candidate ATX-GD-59 demonstrates potential to be the first disease-modifying treatment for Graves' disease and the first potential innovative treatment for the disease in more than 60 years. In addition, Apitope has developed a robust pipeline with several innovative, potential first-in-class product candidates advancing towards clinical development for the treatment of, amongst other indications, uveitis, factor VIII inhibitors, myocarditis, and rheumatoid arthritis. Founded in 2002, Apitope has an experienced leadership team with a strong track record in the pharmaceutical industry and scientific community.